Trial Profile
A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ARTS-DN
- Sponsors Bayer; Bayer HealthCare
- 16 Jan 2023 Results published in the Journal of Hypertension
- 04 Oct 2019 Population pharmacokinetics and pharmacodynamics (PD) analysis for efficacy and safety markers based on data from two clinical phase IIb studies ARTS-DN (NCT01874431) and ARTS DN Japan (NCT01968668); results published in the Clinical Pharmacokinetics
- 01 Sep 2015 Results published in the JAMA: the Journal of the American Medical Association.